Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jayesh Mehta

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 27, 2007
Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timingNirat Beohar, James D Flaherty, Charles J Davidson, et al.
Leukemia & Lymphoma|January 15, 2016
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomideRobert M Rifkin, Rafat Abonour, Jatin J Shah, et al.
The Lancet. Oncology|November 29, 2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jawBeatrice J Edwards, Mrinal Gounder, June M McKoy, et al.
Transplantation|January 17, 2015
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplantsJoseph R Leventhal, Mary J Elliott, Esma S Yolcu, et al.
JAMA Oncology|March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical TrialLocke J Bryan, Carla Casulo, Pamela B Allen, et al.
Clinical Advances in Hematology & Oncology : H&O|December 6, 2007
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedingsEdward A Stadtmauer, Sagar Lonial, David H Vesole, et al.
British Journal of Haematology|March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaRyan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 27, 2007
Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timingNirat Beohar, James D Flaherty, Charles J Davidson, et al.
Leukemia & Lymphoma|January 15, 2016
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomideRobert M Rifkin, Rafat Abonour, Jatin J Shah, et al.
The Lancet. Oncology|November 29, 2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jawBeatrice J Edwards, Mrinal Gounder, June M McKoy, et al.
Transplantation|January 17, 2015
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplantsJoseph R Leventhal, Mary J Elliott, Esma S Yolcu, et al.
JAMA Oncology|March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical TrialLocke J Bryan, Carla Casulo, Pamela B Allen, et al.
Clinical Advances in Hematology & Oncology : H&O|December 6, 2007
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedingsEdward A Stadtmauer, Sagar Lonial, David H Vesole, et al.
British Journal of Haematology|March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaRyan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Pageof 11